Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Abstract Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due t...

Full description

Bibliographic Details
Main Authors: Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach, Philipp J. Jost
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Experimental Hematology & Oncology
Subjects:
MDS
Venetoclax
Combination therapy
Hematotoxicity
HMA failure
Online Access:http://link.springer.com/article/10.1186/s40164-019-0133-1

Internet

http://link.springer.com/article/10.1186/s40164-019-0133-1

Similar Items